When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
CYTR - CytRx up ~4% as Orphazyme reports positive outcome from mid-stage study of Arimoclomol in Gaucher Disease
CytRx Corporation
CytRx (OTCQB:CYTR+4.3%) highlights that Orphayzme announces topline results of Phase 2 dose-finding study with arimoclomol in Gaucher disease (buildup of certain fatty substances in certain organs); In 2011, CytRx sold the rights to arimoclomol to Orphazyme.
More news on: CytRx Corporation, Healthcare stocks news,